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Summary
Lysophosphatidic acid (LPA) is a synaptic phospholipid, which regulates cortical excitation/inhibition (E/I) balance and
controls sensory information processing in mice and man. Altered synaptic LPA signaling was shown to be associated with
psychiatric disorders. Here, we show that the LPA-synthesizing enzyme autotaxin (ATX) is expressed in the astrocytic
compartment of excitatory synapses and modulates glutamatergic transmission. In astrocytes, ATX is sorted toward fine
astrocytic processes and transported to excitatory but not inhibitory synapses. This ATX sorting, as well as the enzymatic
activity of astrocyte-derived ATX are dynamically regulated by neuronal activity via astrocytic glutamate receptors.
Pharmacological and genetic ATX inhibition both rescued schizophrenia-related hyperexcitability syndromes caused by
altered bioactive lipid signaling in two genetic mouse models for psychiatric disorders. Interestingly, ATX inhibition did not
affect naive animals. However, as our data suggested that pharmacological ATX inhibition is a general method to reverse
cortical excitability, we applied ATX inhibition in a ketamine model of schizophrenia and rescued thereby the
electrophysiological and behavioral schizophrenia-like phenotype. Our data show that astrocytic ATX is a novel modulator
of glutamatergic transmission and that targeting ATX might be a versatile strategy for a novel drug therapy to treat cortical
hyperexcitability in psychiatric disorders.
Introduction
Synaptic transmission is a fundamental requirement for
normal brain function [1]. Alterations of transmission at
excitatory synapses are involved in a variety of
neuropsychiatric disorders such as schizophrenia [2, 3].
Proper synaptic transmission relies on the regulation of
neurotransmitters by different processes and is essential for
neuronal communication. Recent research showed that
bioactive phospholipids play an important role in synaptic
neurotransmission and plasticity. Specifically, lysopho-
sphatidic acid (LPA) was shown to affect synaptic strength
and plasticity of central synapses [4–6]. Synaptic LPA is
modulated by the plasticity-related gene 1 (PRG-1) [7],
which is expressed at the postsynaptic density of excitatory
synapses on cortical and hippocampal glutamatergic neu-
rons and plays an important role in maintaining synaptic
homeostasis [4, 6, 8]. Loss of PRG-1-mediated LPA reg-
ulation leads to cortical network hyperexcitability due to a
higher presynaptic glutamate release probability, which is
mediated by increased synaptic LPA levels acting on pre-
synaptic LPA-2 receptors [4]. Recently, a human mutation
(PRG-1R345T) leading to a loss-of-PRG-1 function and a
dysregulation of synaptic LPA signaling was shown to lead
to cortical hyperexcitability and an altered sensorimotor
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gating (pre-pulse inhibition [PPI] in mice and an altered P50
wave in humans), an endophenotype of psychiatric dis-
orders in mice and man [5]. The role of altered synaptic
lipid signaling in psychiatric disorders is supported by
recent data showing that PRG-1-deficiency results in
hypermotility symptoms [9] and is in line with the gluta-
matergic hypothesis of an altered cortical excitation/inhi-
bition (E/I) balance in the pathophysiology of psychiatric
disorders [10–12]. Extracellular LPA is synthesized by
autotaxin (ATX), a lyso phospholipase D (PLD) able to
hydrolyze lysophosphatidyl choline (LPC) to LPA. LPC is
transported across the blood–brain barrier in an Mfsd2a-
dependent manner [13] and is present in the brain in low
concentrations. Thus, the ATX-dependent LPC to LPA
conversion is a rate-limiting step for phospholipid signaling
in the brain. Moreover, LPA is rapidly degraded by lipid
phosphate phosphatases, which are present in the synaptic
compartment [14]. Therefore, as a remote LPA synthesis is
not able to produce synaptic LPA levels necessary for the
modulation of glutamatergic transmission, we aimed to find
the source of synaptic LPA. To this end, we detected the
LPA-synthesizing enzyme ATX in astrocytic perisynaptic
lamellae engulfing excitatory synapses. As pharmacological
inhibition of ATX was effective in decreasing LPA levels
in the cerebrospinal fluid (CSF) [5], we speculated that
inhibiting ATX might be a versatile strategy in treating
pathophysiological states associated with cortical hyper-
excitability. Our data revealed that ATX release from
astrocytes was regulated by glutamate and was dependent
on astrocytic glutamate receptors. Using pharmacological
ATX inhibition and cell type-specific ATX deletion in
astrocytes, we found a reduction in the frequency of min-
iature and spontaneous excitatory postsynaptic currents
(mEPSCs and spEPSCs) to wild-type levels under condi-
tions of hyperexcitability. Moreover, electrophysiological
measurements in freely moving PRG-1-/- mice revealed that
ATX inhibition normalized altered gamma coherence of
cortico–cortical connections, an endophenotype of psy-
chiatric disorders [15]. Using a mouse model expressing a
human PRG-1 loss-of-function single-nucleotide poly-
morphism (SNP; PRG-1R346T), which leads to a dysregu-
lated cortical information processing, and a well-established
ketamine mouse model of schizophrenia [16], we could
demonstrate the efficacy of pharmacological ATX inhibi-
tion in reducing hyperexcitatory cortical states and the
associated characteristic schizophrenia-like phenotypes.
Materials and methods
Mice astrocytic cultures were prepared from P0-P1 mice
cortices according to standard procedures. Briefly,
after removing meninges, cortices were dissociated in
Trypsin-EDTA (Sigma Aldrich, Germany), centrifuged and
re-suspended in Dulbecco’s modified Eagle’s medium
(DMEM) plus 10% fetal bovine serum (FBS), 100 U/ml
penicillin, 100 µg/ml streptomycine (Gibco, Germany) and
2mM L-glutamine (Stem cell technologies, Germany). Cells
were then seeded in poly-L-lysine (10 µg/µl, Sigma Aldrich,
Germany) pre-coated cell culture plates (Greiner Bio-One,
Germany) and maintained in a humidified incubator (5%
CO2). After 3 h of culture, cells were shaken and medium
was renewed. After 7 days in vitro (DIV), cells were shaken
again for removal of possible microglia.
Immunohistochemistry
Brain slices were incubated with antibodies against ATX
(4F1 1:1000) [8, 17], glial fibrillary acidic protein (GFAP,
1:1500), Ezrin (3C12 1:1000, Sigma Aldrich, Germany),
vesicular glutamate transporter 1 (VGluT1) and vesicular
GABA transporter (VGAT) (both 1:1000, Synaptic Sys-
tems, Germany) as described [8]. Electron microscopic
studies were performed as described [4]. For 3,3’-diami-
nobenzidine (DAB) conversion, biotinylated secondary
antibodies were used and DAB staining was performed as
described earlier [4, 18].
Stimulation of astrocytes
After 8–9 DIV, astrocytes were cultivated for 2–4 h in
DMEM without FBS, glutamine or Pen/Strep. The cells were
then stimulated with 500 µM glutamate for 15min and
incubated with fresh DMEM (for western blotting [WB]) or
supplemented with 100 µM C17-LPC (Avanti, USA) for
assessment of ATX activity via mass spectrometry. In control
(i.e., non-stimulated) wells from the same preparation, only
media change were performed. Inhibitors (DL-TBOA [Tocris,
United Kingdom], APV [BioTrend, Germany], DNOX,
LY367385 [Tocris, Germany]) were applied 10 min before
glutamate stimulation. After stimulation, supernatant and cells
were collected at different time points, frozen in liquid
nitrogen and stored at –80 °C until further processing.
Western blotting
Total protein from astrocytes cell culture supernatant was
extracted and concentrated using Vivaspin (Sigma Aldrich,
Germany) centrifugal concentrator according to the produ-
cer’s advice. WB was performed according to standard
procedures as described [19].
Mass spectrometry and confocal live imaging
In all, 100 µl of supernatant was collected from each sample
and directly frozen. After washing, cells were collected,
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pelleted, re-suspended in 50 µl of phosphate-buffered saline,
and frozen at –80 °C. C17-LPA levels of the samples were
measured via mass spectrometry as described [8].
Confocal live imaging of cultivated astrocytes was per-
formed after transfection with 3 µg of ATX-green-
fluorescent protein (GFP)-myc plasmid with Lipofecta-
mine 2000 (Thermo Fisher Scientific, USA). Six to 8 days
after transfection, cells were cultivated for 2 h in non-
supplemented DMEM and imaged at 30 °C using a top-
stage incubator with an inverse confocal Leica SP5 micro-
scope. After baseline imaging, control and stimulated
astrocytes were imaged at the indicated time points where
pictures were taken every 30 s for 5 min. Gray values of
ATX-GFP vesicles in the processes were quantified using
ImageJ and a predefined unbiased threshold (Huang, Ima-
geJ, Bethesda, MD, USA), which allowed detection of
single vesicles.
Mouse lines
PRG-1-/- and ATXfl/fl mice were generated and genotyped as
described [4, 20]. Astrocycte-specific ATX deletion was
obtained by breeding ATXfl/fl mice with a mouse line
expressing Cre under the GFAP promotor [21]. Transgenic
mice expressing the human PRG-1 variant PRG-1R346T were
obtained using CRISPR/Cas9 technology to induce a point
mutation. Hereby a construct was designed to induce a site
mutation resulting in a change from arginine (R; AGG) to
threonine (T; ACG) at position 346 (345 in humans). After
mouse line generation, the PRG-1R346T mutation was con-
firmed by sequencing and off-target search was successfully
performed. By introduction of the site mutation, a restriction
site for BmgBI (5ʹ-CACGTC-3ʹ) was generated, which was
used for further genotyping. All experiments were con-
ducted in accordance with the national laws for the use of
animals in research and with the European Communities
Council Directive 86/609/EEC, and approved by the local
ethical committee (Landesuntersuchungsamt Rheinland-
Pfalz G 12-1-096). Experiments were designed to mini-
mize the number of animals used.
Electrophysiological measurements
All experiments were performed on CA1 neurons in acute
slices from 16 to 19 days old or from 6- to 8-week-old
C57BL/6 mice or on indicated transgenic mice raised on a
C57BL/6 background. The transgenic mouse lines used in
this study are described elsewhere [4, 20]. For field
recordings, slices were kept for at least 1 h at room tem-
perature in an oxygenated ACSF field and pre-warmed for
30 min at 32.5 °C. Slices non-responsive to ketamine
application were excluded. ATX inhibition was performed
using HA130 [5, 22]. Spontaneous, evoked and miniature
excitatory currents (spEPSCs, eEPSCs and mEPSCs) were
acquired with an ELC-03XS amplifier (NPI electronics,
Germany) and using spike 2 software (CED products,
Germany). The signals were filtered at 2 kHz and sampled
at a rate of 10 kHz. Recordings were performed with
GB200F-10 filament microelectrode (3–6MOhm) in cells,
voltage-clamped at –70 mV. spEPSCs and mEPSCs were
pharmacologically isolated with Gabazine (10 µM) and
APV (50 µM) or TTX (0,5 µM) and Gabazine, respectively.
Paired-pulse ratio (PPR) were recorded in CA1 pyramidal
cells by stimulating Schaeffer Collateral fibers with a
bipolar Tungsten electrode at 50 ms inter stimulus interval.
Duration of the pulse was set to 200 µs with the pulse
intensity between 10 and 30 µA. eEPSCs were recorded in
presence of APV, Gabazine and CGP55845 to block
NMDA-, GABAA- and GABAB-receptors, respectively.
PPR was calculated by dividing the mean amplitude of the
second eEPSC by the mean amplitude of the first eEPSC
(average of 20 trials). For ATX inhibition with 1 µM
PF8380, slices were incubated for 1 h before whole-cell
configuration as described [5, 23].
In vivo electrophysiological recordings were performed
as described [24] and were approved by the local autho-
rities. Briefly, anesthetized animals were chronically
implanted with electrodes (WE3PT10.5F3, MicroProbes,
Gaithersburg, MD, USA) in the medial entorhinal cortex
(MEC; 3.1 mm, lateral to the midline, 0.2 mm anterior to the
transverse sinus at an angle of 6° in the anterior-to-posterior
direction in the sagittal plane) and in the hippocampal CA1-
region (1.5 mm lateral to the midline, 1.5 mm anterior-to-
posterior and 1.2 mm dorsal-to-ventral at an angle of 0°).
Neural data were acquired using a 16-channel head stage
and a Digital Lynx data acquisition system (Neuralynx,
USA); the animal’s position was monitored using two light-
emitting diodes mounted on the head stage. To extract local
field potentials (LFPs), the neural signals were bandpass
filtered between 1 and 1000 Hz and digitized at 2 kHz.
Recordings were repeated for 2 days. Recording location
was verified in cresyl violet stained sagittal brain slices.
Field potential analysis
Coherence of neuronal activity between the MEC and in
the CA1 was computed using the multitaper method
(MATLAB routines provided by K. Harris, University
College London, London, UK, and G. Buzsáki, New York
University, New York, NY, USA). Field potentials were
divided into 500 ms segments; coherence was then com-
puted by averaging the cross-spectral densities of two field
potential signals across data windows and tapers and nor-
malizing to the power spectral densities of each signal. To
measure oscillatory power, the LFP signals were convolved
with a series of Morlet wavelets with center frequencies
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ranging from 1 to 100 Hz and a length of three cycles.
Power was calculated by taking the absolute value of the
wavelet transform and averaging across time to obtain the
power spectrum. For statistical analysis, coherence and
power were averaged within the theta (7–12 Hz) and gamma
(30–70 Hz) frequency ranges.
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Behavior
For open field assessment, mice were placed in an arena
(40 × 40 cm) with video tracking and were allowed to freely
explore the chamber. Evaluation of PPI was performed as
described [5]. Briefly, PPI was determined using a 120 dB/
40 ms startle pulse applied alone or preceded by a pre-pulse
stimulus of 70, 75 or 80 dB intensity. Amplitudes of the
startle response were averaged and PPI was calculated as
the percentage of the startle response using the following
formula:
PPI %ð Þ
¼ 100 startle amplitude after pre pulse& pulse
startle amplitude after pulse only
 100
 
Ketamine application for open field (16 mg/kg [16]) and
for PPI (30 mg/kg [25]) assessment was performed as pre-
viously reported. For ATX inhibition, PF8380 was applied
3 h before the experiment (30 mg/kg i.p. in dimethyl sulf-
oxide (DMSO) [23]).
Statistics and data analysis
All statistical analyses were performed with GraphPad
Prism software (version 6). The data are expressed as the
mean ± standard error of the mean (SEM). Appropriate
statistical tests were chosen based on the experimental
condition. Normal distribution of non-normalized data was
assessed using the Kolmogorow–Smirnov test. When nor-
mal distribution was rejected, a non-parametric test was
used. Significance was considered for p ≤ 0.05.
Results
ATX is expressed in perisynaptic astrocytic processes
(PAPs) at the glutamatergic synapse
Using colocalization studies with markers of glutamatergic
(VGluT1) and GABAergic (VGAT) synapses in the adult
brain, we detected abundant ATX expression at excitatory
synapses (Fig. 1a) but no ATX expression at inhibitory
synapses (Fig. 1b). Further analyses using high-sensitivity
immunofluorescence revealed a punctae-like ATX immu-
nosignal and occasional labeling of astrocytic processes
defined by glial fibrillary acidic protein GFAP staining (Fig.
S1A), while labeling of astrocytic cell bodies was hardly
present, as previously described [26]. Colocalization with
ezrin, a marker of PAPs [27], suggested synaptic ATX
expression in dendritic regions (Fig. 1c). Finally, electron
microscopic analysis using DAB precipitation clearly con-
firmed ATX expression in the astrocytic processes sur-
rounding glutamatergic synapses, which are defined by their
asymmetric postsynaptic densities (Fig. 1d and Fig. S1B)
[28]. Interestingly, electron microscopic analyses confirmed
abundant ATX expression in astrocytic processes at exci-
tatory synapses but not at inhibitory synapses in the hip-
pocampal CA1-region (Figs. 1e, f), as well as in the cortex,
as shown in the layer 4 of the auditory cortex (Fig. S1C,D).
This suggests an intracellular sorting of ATX in astrocytes
toward the astrocytic processes covering excitatory
synapses.
Astrocytic ATX secretion and activity are regulated
by glutamatergic signaling
In order to understand this specific ATX expression pattern,
we performed live imaging of primary astrocytes expressing
Fig. 1 ATX is expressed by perisynaptic astrocytic processes (PAPs)
at excitatory synapses and is regulated by glutamate. a, b ATX shows
abundant colocalization with VGluT1, a marker of excitatory synap-
ses, but not with VGAT, a marker of inhibitory synapses. c ATX is
expressed at PAPs as shown by colocalization with Ezrin, a specific
marker for PAPs. Scale bars a–c: 1 µm. d Electron microscopic image
showing ATX expression (displayed by DAB-precipitation [red
asterisk] at the astrocytic membrane close to the synapse) on PAP
membranes surrounding glutamatergic synapses. Dense membrane in
the postsynaptic compartment (red arrow) represents the postsynaptic
density (PSD) of glutamatergic synapses (see also Fig. S1B). e
Immune electron microscopic analysis revealed no ATX expression in
astrocytic processes (white asterisk) at inhibitory synapses (white
arrow). In contrast, ATX expression (shown by DAB precipitation)
was prominent in astrocytic processes (red asterisk) at excitatory
synapses (red arrow, see also Fig. S1C,D). f Higher magnification
showing the inhibitory synapse (white arrow) and the adjacent ATX-
negative astrocytic process (white asterisk). Scale bars d–f: 200 nm.
G1-I1 Live imaging of astrocytes transfected with an ATX-GFP-
expressing construct shows a clear increase of ATX-GFP-positive
vesicles transported along their processes towards the periphery after
glutamate stimulation (500 µM for 15 min). G2-I2 Live-imaging pic-
tures at higher magnification show transport of ATX-GFP-positive
vesicles (white arrow heads) along an astrocytic process from the cell
body (cb) toward the periphery (p). In contrast, ATX-GFP-positive
vesicles were rarely seen in processes of control, non-stimulated
astrocytes (Fig. S1E). j Quantitative analysis of ATX-GFP vesicles in
astrocytic processes, during glutamate stimulation and at 0, 30 and
60 min after glutamate stimulation (n= 13 control astrocytes and 14
glutamate-stimulated astrocytes; two-way RM ANOVA with Bonfer-
roni post hoc). k ATX secretion in the astrocytic culture supernatant
was significantly increased upon glutamate stimulation (500 µM Glut
stimulation for 15 min) when compared with supernatant from control
(c), non-stimulated astrocytic cultures as shown by western blot (n= 5
for 2 h values and n= 4 for 4 h values, two-tailed t-test). l C17-LPA
synthesis in the astrocytic compartment was significantly decreased
upon application of specific glutamate receptor inhibitors (50 µM
LY367385 for mGluR1a, 50 µM APV for NMDA-Rs and 10 µM
DNQX for AMPA-Rs), whereas 40 µM DL-TBOA, an inhibitor of
astrocytic glutamate transporters, did not affect astrocytic C17-LPA
levels as shown by mass spectrometry analyses (n= 6 experiments per
group, one-way RM ANOVA with Bonferroni post hoc). Bars repre-
sent mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001
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an ATX–GFP fusion protein. In the culture setting devoid
of the neuronal compartment, astrocytes displayed only
sparse ATX–GFP signals along their processes (Fig. S1E).
However, after glutamate stimulation we detected a clear
transport of ATX–GFP vesicles along astrocytic processes
(Figs. 1g-j), which suggests a dynamic regulated intracel-
lular ATX sorting and ATX transport along astrocytic
processes toward excitatory synapses by glutamatergic
signaling. As ATX is a transmembrane protein with a cat-
alytic domain facing the extracellular space, where it is
eventually shed [29], we speculated that ATX is released
from astrocytic processes in a glutamate-dependent manner
and exhibits its enzymatic activity converting LPC to LPA
in the synaptic space. Indeed, we detected a significant
increase in ATX levels in the supernatant of cultured
astrocytes upon glutamate stimulation (Fig. 1k). Moreover,
after adding the unnatural precursor C17-LPC we detected a
clear increase in ATX´s enzymatic activity and found sig-
nificantly increased levels of newly synthesized C17-LPA
upon glutamate stimulation (Fig. S1F-K). Here, C17-LPA
reached significantly higher levels within 3 min after glut-
matergic stimulation (when compared with non-stimulated
conditions, Fig. S1J). We then characterized glutamate
signaling pathways involved in astrocytic ATX upregula-
tion and inhibited astrocytic glutamate transporters (using
TBOA), as well as glutamate receptors present on astrocytes
(α-amino-3-hydroxyl-5-methyl-4-isoxazolepropionic acid
receptor (AMPA), N-methyl-D-aspartate receptor (NMDA),
mGluR1a). Although blocking glutamate transporters did
not affect glutamate-induced increase of enzymatic ATX
activity, inhibition of AMPA, NMDA or mGluR1a recep-
tors (using the specific inhibitors DNQX, APV and
LY367385, respectively) significantly inhibited glutamate-
dependent increase of ATX activity (Fig. 1l). In sum, our
data indicate that glutamate released from presynaptic
terminals acts on glutamatergic receptors present on astro-
cytes where it induces ATX-sorting and ATX-transport
toward excitatory synapses. At the synapse, ATX is
released and is able to exert its enzymatic function by
converting LPC to LPA in the synaptic cleft.
ATX inhibition normalizes cortical hyperexcitability
and behavior in two animal models of psychiatric
disorders
As recently reported, increased synaptic LPA levels aug-
mented mEPSCs frequency but not their amplitudes,
pointing to an increased presynaptic release probability.
However, disruption of LPA signaling at glutamatergic
synapses (by deletion of the presynaptic LPA2 receptor)
reduced mEPSCs frequency in conditions of glutamate-
mediated cortical hyperexcitability in PRG-1-/- animals [4,
8]. We therefore used PRG-1-/- animals and inhibited ATX
using PF8380 [5, 23] finding that ATX inhibition reduced
both mEPSC and spontaneous (sp)EPSC frequencies to
control levels (Figs. 2a-c and Fig.S2B-D). However, ATX
inhibition did not alter mEPSC or spEPSC frequencies in
wild-type slices (Figs. 2a-c and Fig. S2A,C,D) and had no
effect on wild-type animal behavior (Fig. S2E,F). In line,
cortical hyperexcitability in PRG-1-/- animals was rescued
by cell type-specific genetic deletion of ATX in astrocytes
(using a PRG-1-/-/ATXfl/fl/GFAP-Cre mouse line, Figs. 2a-
c). However, in wild-type animals, which display normal
cortical excitability, astrocytic ATX deletion did not alter
neuronal activity or animal behavior (Fig. S2G-L) sup-
porting the idea of a specific effect of ATX inhibition in
conditions of cortical hyperexcitability. Interestingly, in
addition to normalizing cortical hyperexcitability, ATX
inhibition rescued presynaptic plasticity (Fig. 2d), which is
altered in PRG-1-/- neurons as previously described [8].
Here, ATX inhibition decreased the first EPSC (eEPSC1)
corroborating the presynaptic action of synaptic LPA and
supporting the idea that higher synaptic LPA levels increase
presynaptic release probability and impair thereby short-
term presynaptic plasticity (Fig. 2e). In sum, these data
suggest that cortical hyperexcitability is regulated by
synaptic LPA and that ATX inhibition is a selective and
versatile strategy to normalize glutamate-induced hyper-
excitable cortical states.
To assess the effect of cortical hyperexcitability in vivo,
we performed simultaneous field potential recordings of
hippocampal CA1 neurons and of layer II/III entorhinal
cortex neurons (which connect to hippocampal CA1 neu-
rons) in freely moving PRG-1-/- animals and in wild-type
litters (Fig. S3A). Here, we found that the hyperactive
cortical state present in PRG-1-/- animals [4, 6, 8] resulted in
a significant increase in the mean gamma coherence
(Figs. 2f, g and Fig S2B), which is typically altered in
patients with psychiatric disorders like schizophrenia [15,
30]. To examine the utility of ATX inhibition as a potential
therapeutic option, we treated PRG-1-/- animals with the
ATX-inhibitor PF8380 [23]. This was highly effective at
reducing LPA moieties in the CSF (Fig. 2h and Fig. S3C)
and rescued mean gamma coherence to wild-type levels
(Figs. 2f, g). Moreover, ATX inhibition decreased hyper-
motility of PRG-1-/- mice in an open field setting (Fig. S3D-
F), which is a typical symptom for psychiatric disorders and
was reported to be mediated by loss of PRG-1-mediated
regulation of synaptic LPA levels [9]. To directly prove the
idea that loss of synaptic LPA regulation and subsequent
increase in cortical excitability induces an endophenotype
for psychiatric disorders, we analyzed transgenic animals
expressing a previously described human SNP of PRG-1,
which leads to a loss of PRG-1's regulatory function (PRG-
1R346T [5]). Here, the PRG-1R346T mutation induced an
altered glycosylation leading to a loss of PRG-1´s ability to
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take up LPA (see also Figure S3G-I). Interestingly, human
carriers of this mutation (PRG-1R345T) displayed changes in
sensory information processing (as shown by altered P50
values), which are regarded as an endophenotype for schi-
zophrenia [5]. We found significantly reduced PPI values in
PRG-1+/R346T mice (Fig. 2i), which reflect a sensorimotor
cortical filter function. PPI analyzes are a long-standing
paradigm related to psychiatric diseases like schizophrenia
for which humans and rodents are assessed in similar
manner [31]. In order to test our findings on this endo-
phenotype, we treated the PRG-1+/R346T carrier mice with
PF8380. Here, ATX inhibition normalized the reduced PPI
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startle responses to wild-type levels (Fig. 2i) and corrobo-
rated the idea of ATX inhibition as a therapy for psychiatric
disorders.
ATX inhibition is an effective treatment in a
ketamine-induced animal model of schizophrenia
As alterations in gamma coherence play a role in psychiatric
disorders [30, 32] and ATX inhibition specifically normal-
ized this electrophysiological phenotype, as well as the
cortical sensorimotor gating deficit (PPI), we speculated that
inhibiting ATX might be an overarching strategy to tackle
hyperexcitable cortical states. We therefore analyzed the
effect of ATX inhibition in the well-established ketamine
model of schizophrenia [16]. Here, short-term application
of ketamine induced cortical hyperexcitability as shown
by an increase in field potentials (Figs. 3a, b). However,
application of HA130, an ATX-inhibitor with short-term
action in vitro [5, 22] (Fig. S4A), significantly reduced this
increase to baseline levels (Figs. 3a, b). In line with this,
analysis of input/output curves, which reflect neuronal
excitability, revealed a significant increase after ketamine
application, which was significantly reduced following
HA130 application (Fig. 3c, Fig. S4C). As ketamine appli-
cation in vivo results in characteristic behavioral changes
related to schizophrenia [16], we analyzed the efficacy of
ATX inhibition on reversing these behavioral psychiatric
phenotypes. Hereby, we found that ATX inhibition by
PF8380 effectively rescued PPI startle responses in this
animal model of schizophrenia to wild-type levels (Fig. 3d
and Fig S4D) and significantly reduced locomotor hyper-
activity, which is a schizophrenia-resembling positive
symptom and was characteristically displayed after ketamine
application (Fig 3e). In sum, our data suggest that ATX
inhibition is a versatile new strategy for tackling cortical
hyperexcitability associated with psychiatric disorders.
Discussion
Bioactive lipid signaling at the synapse has been shown to
stimulate glutamatergic transmission, both in the hippo-
campus [4] and in the somatosensory cortex [6]. This
pathway is mediated by LPA acting on G protein-coupled
LPA receptors, which induce intracellular signaling [33]. At
the synapse, LPA acts on presynaptic LPA2 receptors
thereby increasing the presynaptic glutamate release prob-
ability [4, 8]. In turn, synaptic LPA appears to be under
control of a postsynaptic regulator, PRG-1, which regulates
synaptic LPA levels via a cellular uptake mechanism [5].
Thereby postsynaptic PRG-1 regulates LPA stimulation of
presynaptic LPA2 receptors, which in turn modulate pre-
synaptic glutamate release probability [4]. The source of
synaptic LPA, which has yet to be identified, is a critical
point in LPA signaling because LPA is a short-lived
molecule that is readily degraded by lipide phosphate
phosphatases [34]. Moreover, LPA rapidly integrates into
membranes, and is only slightly soluble in aqueous solu-
tions such as the CSF, where it is present in low con-
centrations [35]. Thus, synaptic LPA signaling requires an
—as of yet unclear—local LPA source close to its point of
action at the synapse. LPA is synthesized in the extra-
cellular space by the lysoPLD ATX, which hydrolyzes LPC
to LPA [36, 37]. Although in the blood LPC is abundant, it
is actively transported across the blood–brain barrier and is
present in the CSF only in minimal concentrations [35]. The
Fig. 2 ATX inhibition rescues neuronal hyperexcitability and PPI
deficits in PRG-1-deficient animals. a Miniature excitatory post-
synaptic currents (mEPSCs) in CA1 pyramidal neurons of wild-type
(WT) slices were not affected by ATX inhibition with 1 µM PF8380.
However, in PRG-1-/- slices, which display higher mEPSC frequency,
ATX inhibition significantly diminished mEPSC frequency to WT
levels. In line, astrocyte-specific ATX deletion significantly decreased
mEPSC frequency in PRG-1-/- animals to WT levels. Amplitudes (see
Fig. S2C) were not affected supporting a presynaptic effect (n= 13
WT neurons, 8 PF8380-treated WT neurons, 10 PRG-1-/- neurons, 10
PF8380-treated PRG-1-/- neurons and 10 PRG-1-/-/ATXfl/fl:GFAP-Cre+
neurons; one-way ANOVA with Bonferroni post hoc). b Original
traces showing spontaneous excitatory postsynaptic currents
(spEPSCs) of neurons under different conditions. c Although ATX
inhibition via PF8380 application did not alter spontaneous excitatory
(spEPSCs) frequency in WT slices, higher spontaneous frequency
observed in PRG-1-/- neurons was significantly decreased to WT
levels. Similarly, genetic deletion of ATX in astrocytes decreased
spontaneous excitatory frequency in PRG-1-/- neurons to WT levels,
whereas amplitudes were not affected (see Fig. S2D) (n= 11 WT
neurons, 12 PF8380-treated WT neurons, 19 PRG-1-/- neurons, 17
PF8380-treated PRG-1-/- neurons and 18 PRG-1-/-/ATXfl/fl:GFAP-Cre+
neurons; Kruskal–Wallis test with Dunn’s multiple comparisons post
hoc test). d Paired-pulse ratio (PPR) in PRG-1-/- animals was sig-
nificantly increased after ATX inhibition. e ATX inhibition by PF8380
decreased the first eEPSC(1) in PRG-1-/- animals. f Coherence analysis
of simultaneous recordings of field potentials in layer II/III of the
medial entorhinal cortex (MEC) and the hippocampal CA1 in freely
moving mice revealed significantly higher coherence in the gamma
range (30–70 Hz, dashed box) in PRG-1-/- mice. Interestingly, LPA
reduction by application of the ATX inhibitor PF8380 reduced this
coherence in PRG-1-/- mice to WT level (see also Fig. S3A, D-F). g
Quantitative analysis revealed significantly increased mean gamma
coherence in PRG-1-/- mice, which was reduced to WT levels upon
PF8380-treatment (n= 15 WT mice, 12 untreated PRG1-/- and 7
PF8380-treated PRG1-/- mice; one-way ANOVA with Bonferroni post
hoc; see also Fig S3B). h In order to assess the efficiency of ATX
inhibition by PF8380, LPA levels were measured in the CSF after
PF8380 application (30 mg/kg body weight). Here, we found a clear
decrease in the main LPA species (LPA 16:0, 18:1, 18:2 and 20:4; n=
6 for all groups; one tailed, Mann–Whitney test; see also Fig. S2C). i
Pre-pulse inhibition (PPI) at all tested loudness levels was significantly
decreased in a mouse line expressing a monoallelic human PRG-1
single-nucleotide polymorphism (SNP). However, PF8380 application
rescued decreased PPI to WT levels (n= 9 WT mice, 15 untreated
PRG1+/R346T and 15 PF8380-treated PRG1+/R346T mice; one-way
ANOVA with Bonferroni post hoc; see also Fig. S3G-I). Bars repre-
sent mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001
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low availability of the LPA precursor LPC in the brain
together with the rapid degradation of LPA makes the
source of synaptic LPA a critical factor for synaptic LPA
signaling.
ATX expression in PAPs is a characteristic feature of
excitatory cortical synapses and fuels glutamatergic
synaptic lipid signaling
Electron microscopic analyzes revealed ATX-expressing
PAPs, which were found adjacent to asymmetric,
excitatory cortical synapses but not to inhibitory synapses.
Together with previous reports showing that LPA
signaling at glutamatergic synapses is mediated by the
presynaptic LPA2 receptor and is regulated by the post-
synaptic LPA-interacting molecule PRG-1 [4, 5], our
data describe a novel molecular mechanism regulating
glutamatergic transmission at the tripartite glutamatergic
synapse. This synaptic ATX localization is optimally
suited to provide fast local LPA levels at a timescale
necessary for modulation of glutamatergic transmission.
Importantly, astrocytic ATX release and increased LPA
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Fig. 3 ATX inhibition effectively reduced cortical hyperexcitability,
PPI and hyperlocomotion in an animal model for schizophrenia. a
Representative evoked field potentials of control and 10 µM HA130-
treated slices before and after ketamine stimulation. Note the poten-
tiation after ketamine application and the rescued field potentials after
HA130 application on ketamine-treated slices. Dotted red lines depict
control levels. b After an initial depression, ketamine application leads
to a significant neuronal potentiation as shown by evoked field
potential recordings (1 stimulation every 30 s; for amplitudes see Fig.
S4B). However, ATX inhibition by HA130 significantly reduced
ketamine potentiation back to baseline levels (n= 8 Ketamine and 7
Ketamine + HA130 (10 µM)-treated slices; two-way RM ANOVA
and Bonferroni multiple comparison post hoc test). c Input/output
(I/O) assessment of slopes using increasing stimulus intensities shows
that HA130 application significantly decreased I/O-relationship (n= 6
Ketamine and 5 ketamine + HA130 (10 µM)-treated slices, two-way
RM ANOVA and Bonferroni multiple comparison post hoc test; see
also Fig. S4C). d Pre-pulse inhibition (PPI) was significantly reduced
in ketamine-treated animals but restored to WT levels by ATX inhi-
bition via in vivo application of PF8380. Startle amplitudes were not
altered by ketamine application or by ATX inhibition (n= 13 control
animals, 13 ketamine-treated animals and 16 ketamine+ PF8380-
treated animals; one-way ANOVA with Bonferroni’s multiple com-
parisons test; see also Fig. S4D) e Ketamine induced significant
hyperlocomotion in an open field (OF) setting, whereas in vivo inhi-
bition of ATX via PF8380 administration reduced ketamine-induced
hyperlocomotion to WT levels (n= 14 control animals, 14 ketamine-
treated animals and 15 ketamine+ PF8380-treated animals; two-way
RM ANOVA and Sidak’s multiple comparison post hoc test). Bars
represent mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001
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production were dynamically regulated in a glutamate-
dependent manner, which involved astrocytic AMPA and
NMDA receptors. These data suggest that the ATX/LPA/
LPA2 signaling axis might act as a feed-forward
enhancer following neuronal activity: at the synapse,
increased glutamate levels following neuronal firing would
result via astrocytic stimulation in increased synaptic LPA
levels, which in turn would enhance the presynaptic gluta-
mate release probabilities. Indeed, these effects were
observed in PRG-1-/- animals where the PRG-1-dependent
regulation is missing [4, 6, 8]. The specific effect of
synaptic ATX was further corroborated by cell type-specific
genetic deletion of ATX in astrocytes, which rescued neu-
ronal hyperexcitability in PRG-1-/- animals to wild-type
levels. Moreover, ATX inhibition rescued disturbed pre-
synaptic plasticity in PRG-1-/- mice confirming the pre-
synaptic action of synaptic LPA. In sum, our data suggest
that ATX is a key molecule within a stimulatory feed-
forward mechanism of excitatory transmission and is in line
with recent reports suggesting that astrocytes are a novel
regulatory element of excitatory synaptic function acting via
lipid-mediated pathways [38].
Inhibition of ATX as a new strategy for treating
psychiatric disorders
Shifts in the (E/I) balance of cortical networks toward a
higher excitability leading to pathological cortical infor-
mation processing have been suggested to contribute to
the pathophysiology of psychiatric disorders like schizo-
phrenia and are considered biomarkers/endophenotypes for
this disorder [3, 10, 12, 39–41]. Using different genetically
modified mouse lines where alterations in synaptic
lipid signaling resulted in a cortical network hyperexcit-
ability (PRG-1-/- described in Trimbuch et al. [4] and
PRG-1R346T, expressing a human PRG-1 mutation described
in Vogt et al. [5]) we found a significant augmentation
of gamma coherence, a pathological PPI and hyperloco-
motion. These findings are of specific importance as these
symptoms have been implicated in psychiatric disorders
like schizophrenia [30, 32, 42, 43], and were normalized
to wild-type levels by ATX inhibition. Moreover, they
provided a strong argument to consider ATX inhibition as
a general therapeutic approach to treat cortical hyper-
excitable states. We therefore analyzed the effect of ATX
inhibition in a well-described animal model for schizo-
phrenia, where application of ketamine increased cortical
excitability as recently described in mice and related to
findings in human schizophrenia patients [16]. Here, ATX
inhibition was effective in normalizing both neuronal
hyperexcitation, as well as pathological behaviors including
PPI and hyperlocomotion in this animal model for schizo-
phrenia demonstrating the suitability of targeting synaptic
bioactive lipid signaling as a potential therapy for psy-
chiatric disorders.
ATX inhibition by small inhibiting molecules like
PF8380 is a rapidly evolving treatment strategy, which
was used for chronic inflammation and cancer with a
potential therapeutic benefit [44], as well as for treating air-
pouch inflammation [23], collagen-induced arthritis [45],
bleomycin-induced pulmonary inflammation and fibrosis
[46], allergen-induced asthma [47], or metastasis of mela-
noma and breast cancer cells [45–52]. Moreover, our data
showing that ATX inhibition under physiological condi-
tions does not alter cortical electrophysiology and does not
affect animal behavior suggests that ATX inhibition is a
versatile strategy for treating cortical hyperexcitatory states
present in psychiatric disorders while not affecting indivi-
duals with physiological brain states.
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